Page last updated: 2024-11-04

bemegride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bemegride: A CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2310
CHEMBL ID1214192
CHEBI ID92269
SCHEMBL ID601065
MeSH IDM0002301

Synonyms (107)

Synonym
AKOS001108082
BRD-K14993104-001-03-4
CHEMBL1214192
2,6-piperidinedione, 4-ethyl-4-methyl-
malysol
3-ethyl-3-methylglutarimide
bemegride
nsc58187
agipnon
4-methyl-4-ethyl-2,6-dioxopiperidine
.beta.-methyl-.beta.-ethylglutarimide
zentraleptin
wln: t6vmvtj e2 e1
3-methyl-3-ethylglutarimide
bemegrid
3,3-methylethylilotarimide
megibal
mikedimide
benegrid
.beta.-ethyl-.beta.-methylglutarimide
2,6-dioxo-4-methyl-4-ethylpiperidine
megimide
megimid
bemigride
np 13
64-65-3
np13
2, 4-ethyl-4-methyl-
antibarbi
ahypnon
methetharimide
glutarimide, 3-ethyl-3-methyl-
eukraton
nsc-58187
4-ethyl-4-methyl-2,6-dioxopiperidine
4-ethyl-4-methyl-2,6-piperidinedione
ai3-52526
brn 0116672
beta-methyl-beta-ethylglutarimide
einecs 200-588-0
bemegridum [inn-latin]
nsc 58187
beta-ethyl-beta-methylglutarimide
bemegrida [inn-spanish]
NCGC00016288-01
cas-64-65-3
BPBIO1_000732
NCGC00179483-01
PRESTWICK2_000882
BSPBIO_000664
PRESTWICK3_000882
AB00376458
megibal (tn)
D01957
bemegride (jan/inn)
PRESTWICK1_000882
SPBIO_002883
PRESTWICK0_000882
orrzgubhbvwwop-uhfffaoysa-
3-ethyl-5-methyl-piperidine-2,6-dione
inchi=1/c8h13no2/c1-3-8(2)4-6(10)9-7(11)5-8/h3-5h2,1-2h3,(h,9,10,11)
E0284
HMS1570B06
4-ethyl-4-methylpiperidine-2,6-dione
A834846
4-ethyl-4-methyl-piperidine-2,6-dione
HMS2097B06
bemegride [usp:inn:ban:jan]
57dqa39do2 ,
unii-57dqa39do2
bemegridum
bemegrida
dtxsid0045250 ,
dtxcid8025250
tox21_110352
S4197
NCGC00016288-02
FT-0631285
bemegride [who-dd]
bemegride [mart.]
bemegride [jan]
bemegride [mi]
bemegride [inn]
SCHEMBL601065
CCG-220882
ORRZGUBHBVWWOP-UHFFFAOYSA-N
CS-4896
Z99599698
HY-B1326
AB00376458_04
mfcd00006673
sr-01000872683
SR-01000872683-1
CHEBI:92269
HMS3652P09
HMS3714B06
SW197218-3
BCP18663
F17053
DB13740
DS-16419
Q792614
HMS3885L09
3-ethyl-3-methylglutarimide;bemegrid
NCGC00016288-06
2,6-piperidinedione,4-ethyl-4-methyl-
EN300-18941

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Dosage and injection rate must be chosen in such a way that false negative results are more probable than false positive."( [EEG activation with bemegride in epilepsy diagnosis. 1: Literature review].
Bülau, P; Fröscher, W, 1984
)
0.59
" Pretreatment with the convulsant bemegride antagonized the pentobarbital transfer but not the chlordiazepoxide cue, whereas the specific benzodiazepine antagonist RO15-1788 decreased the chlordiazepoxide cue in a dose-response manner without attenuating the pentobarbital transfer."( Specific antagonism of the behavioral effects of chlordiazepoxide and pentobarbital in the rat.
Schechter, MD, 1984
)
0.55
" Tests with combinations of DZP and ETOH produced a shift of the dose-response curves to the left indicating drug additivity."( Interaction of the discriminative stimulus properties of diazepam and ethanol in pigeons.
Järbe, TU; McMillan, DE, 1983
)
0.27
" Dosage below 25 mg."( A barbiturate antidote. Use of methylethyl-glutarmide in barbiturate intoxication and in terminating barbiturate anesthesia.
MARMER, MJ, 1959
)
0.24
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperidones
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency22.38720.177814.390939.8107AID2147
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.52200.000229.305416,493.5996AID743080
cytochrome P450 2C19 precursorHomo sapiens (human)Potency6.30960.00255.840031.6228AID899
lamin isoform A-delta10Homo sapiens (human)Potency11.22020.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID496866Anticonvulsant activity in po dosed mouse assessed as inhibition of MES-induced tonic seizures2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (445)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990423 (95.06)18.7374
1990's8 (1.80)18.2507
2000's3 (0.67)29.6817
2010's9 (2.02)24.3611
2020's2 (0.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.42 (24.57)
Research Supply Index6.26 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (1.17%)5.53%
Reviews10 (1.95%)6.00%
Case Studies12 (2.33%)4.05%
Observational0 (0.00%)0.25%
Other486 (94.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]